“Hello, My Name Is”
Editor's Note: This article was originally written and shared with us by Nick Leon of Naked Eye, and is shared here with gratitude. To see the article in its original…
Continue Reading
“Hello, My Name Is”
MediciNova Advances Intellectual Property for Glioblastoma Combination Therapy
As reported by The Manila Times, MediciNova has announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a new patent application involving its investigational…
Continue Reading
MediciNova Advances Intellectual Property for Glioblastoma Combination Therapy
Otsuka’s Voyxact Advances IgA Nephropathy Treatment Landscape with Phase 3 Data
According to a recent report on BioSpace, Otsuka Pharmaceutical’s investigational therapy Voyxact is gaining momentum in IgA nephropathy (IgAN) after new Phase 3 results showed meaningful preservation of kidney function,…
Continue Reading
Otsuka’s Voyxact Advances IgA Nephropathy Treatment Landscape with Phase 3 Data
Duchenne Families Made the Sacrifices Asked. FDA Withheld the Hope.
Editor's Note: This story was submitted to us by Angelina Olivera, the mom of a 14-year-old with Duchenne muscular dystrophy, and the sister of two brothers who died from Duchenne…
Continue Reading
Duchenne Families Made the Sacrifices Asked. FDA Withheld the Hope.
FDA Extends Review of AstraZeneca’s Investigational Breast Cancer Therapy
As reported in BioPharmaDive, the U.S. Food and Drug Administration (FDA) has postponed its decision on camizestrant, an experimental oral therapy for breast cancer being developed by AstraZeneca, following a…
Continue Reading
FDA Extends Review of AstraZeneca’s Investigational Breast Cancer Therapy
HAYA Therapeutics Advances First-in-Class RNA Therapy Into Phase 1 for Cardiac Fibrosis in nHCM
As reported on PharmaBiz, HAYA Therapeutics has reached an early clinical milestone with its lead investigational therapy, HTX-001, announcing that the first cohort of participants has been enrolled and treated…
Continue Reading
HAYA Therapeutics Advances First-in-Class RNA Therapy Into Phase 1 for Cardiac Fibrosis in nHCM
The Child Who Defied the Textbooks
The human body is governed by an ancient, rapid-response defense system. When an invader attacks, the innate immune system rushes to the front lines like firefighters to a blaze. But…
Continue Reading
The Child Who Defied the Textbooks
Dear Cancer, Three Years Have Gone By
Editor's Note: This story was originally written by Julia Alessandrine—a survivor of Hodgkins Lymphoma—and shared with us by our friends at Elephants & Tea. To see the article in its…
Continue Reading
Dear Cancer, Three Years Have Gone By
The Heart Behind Every Clinical Trial
Editor's Note: This article was submitted to us by Regina Portnoy. A clinical trial may be remembered for a breakthrough treatment, a new therapy, or a headline-making discovery. But its…
Continue Reading
The Heart Behind Every Clinical Trial
Resilience During Adversity
Having lived with chronic pain and involuntary muscle contractions from a neurological movement disorder called dystonia since 2001, I felt defeated many times. But I am still here battling every…
Continue Reading
Resilience During Adversity
From Denial to Balance: My Journey with Lupus
Looking back, the signs were there long before I was diagnosed with lupus. As a child, I struggled with gastrointestinal issues and a variety of symptoms that suggested something wasn't…
Continue Reading
From Denial to Balance: My Journey with Lupus
Ultrasounds and Pain
Imagine being able to turn down the dial on severe pain without taking a single pill or undergoing surgery. Scientists in the UK have just taken a major step toward…
Continue Reading
Ultrasounds and Pain
A Systemic Mastocytosis Journey: From Diagnosis to Advocacy
Editor's Note: Patient Worthy is honored to present this story, shared with us by our friends at The Mast Cell Disease Society. To see the article in its original format,…
Continue Reading
A Systemic Mastocytosis Journey: From Diagnosis to Advocacy
Daraxonrasib Is Promising. But Here’s What Pancreatic Cancer Patients Need to Know First
By Dr. Avishek Kumar When someone hears there may finally be a breakthrough for pancreatic cancer, the natural reaction is hope. In clinic, however, I often see what comes next.…
Continue Reading
Daraxonrasib Is Promising. But Here’s What Pancreatic Cancer Patients Need to Know First
Heart Attacks and Your Brain
1. A Physical Smoking Gun in the Heart-Brain Connection When people experience cognitive problems, mood drops, or chronic anxiety after surviving a heart attack, the medical community traditionally viewed it…
Continue Reading
Heart Attacks and Your Brain
Infex Therapeutics Reports Positive Phase IIa Data for RESP‑X in Bronchiectasis Patients with Pseudomonas Colonisation
As reported on PharmaBiz, Infex Therapeutics has announced encouraging results from a phase IIa clinical study of RESP‑X, an investigational monoclonal antibody being developed for patients with non‑cystic fibrosis bronchiectasis…
Continue Reading
Infex Therapeutics Reports Positive Phase IIa Data for RESP‑X in Bronchiectasis Patients with Pseudomonas Colonisation
Cingulate Receives FDA Complete Response Letter for ADHD Candidate Over Manufacturing Issues
As reported on FiercePharma, Cingulate Therapeutics has encountered a regulatory setback in its effort to bring its lead attention-deficit/hyperactivity disorder (ADHD) therapy to market, after the U.S. Food and Drug…
Continue Reading
Cingulate Receives FDA Complete Response Letter for ADHD Candidate Over Manufacturing Issues
Should vs. Want: Guiding Insights from a Palliative Care Clinician
Editor's Note: This article was originally written by Joanne Huff, and shared with us by our friends at the Courageous Parents Network. To see the article in its original format,…
Continue Reading
Should vs. Want: Guiding Insights from a Palliative Care Clinician
Efdoralprin Alfa Shows Superior Efficacy Over Standard Augmentation Therapy in AATD Emphysema
As reported on PharmaBiz, new findings from the phase 2 ElevAATe trial suggest that the investigational agent efdoralprin alfa may represent a meaningful advance in the treatment of alpha-1 antitrypsin…
Continue Reading
Efdoralprin Alfa Shows Superior Efficacy Over Standard Augmentation Therapy in AATD Emphysema
FDA Clears First Oral Medication for Post-Exposure COVID-19 Prevention
As reported on Beckers Hospital Review, the U.S. Food and Drug Administration has authorized ensitrelvir (brand name Xocova) as the first oral antiviral indicated for post-exposure prophylaxis of COVID-19 in…
Continue Reading
FDA Clears First Oral Medication for Post-Exposure COVID-19 Prevention
Hidden for Six Weeks: How My Brain Injury Revealed Itself
To this day, I still don't remember the car accident that changed my life. It was Thursday, August 8, 2024 — a day like any other. I'd gone to BioFit,…
Continue Reading
Hidden for Six Weeks: How My Brain Injury Revealed Itself
FDA Priority Review Signals Potential Breakthrough for Limb-Girdle Muscular Dystrophy
As reported on BioSpace, the U.S. Food and Drug Administration (FDA) has granted priority review to BridgeBio Pharma’s investigational therapy, BBP-418, marking a key regulatory milestone for a condition that…
Continue Reading
FDA Priority Review Signals Potential Breakthrough for Limb-Girdle Muscular Dystrophy
A Deeper Dive into the Ebola Virus
Formally known as Ebola hemorrhagic fever, Ebola is often fatal in humans. The disease is transmitted through contact made with body fluids or blood of from a person who died…
Continue Reading
A Deeper Dive into the Ebola Virus
International Clinical Trials Day
Editor's Note: This article was originally written and shared with us by Caleigh Haber. This day hits really close to home for me. I was born with Cystic Fibrosis in…
Continue Reading
International Clinical Trials Day
GSK’s Arexvy Gains Expanded Approval in Japan to Include Younger High-Risk Adults
As reported by PharmaBiz, Japan’s Ministry of Health, Labour and Welfare (MHLW) has broadened the approved use of GSK’s respiratory syncytial virus (RSV) vaccine, Arexvy, to cover adults aged 18–49…
Continue Reading
GSK’s Arexvy Gains Expanded Approval in Japan to Include Younger High-Risk Adults
- Go to the previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- …
- 23
- Go to the next page
